← Leaderboards
Nan Wang
Columbia University Health Sciences
$8,758,079
Attributed
$8,758,079
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,758,079 · 5
By mechanism
R01$6,620,752 · 3
P01$2,137,327 · 2
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Alan Richard Tall$42,229,886
- Ira A Tabas$44,847,082
- Henry N Ginsberg$119,772,603
- Muredach P Reilly$136,077,018
- Lars F Berglund$52,226,926
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisCellsAtherogenesisArterial Fatty StreakMacrophageRisk FactorsMediatingNeutrophilProductionLesionCardiovascular Disorder RiskBlood PlateletsMonocyteCoronary Heart DiseaseGenetic VariantLinkMouse ModelMutationBlood CellsHematopoieticDiabetes MellitusAtherothrombosisMyeloproliferative DiseaseJak2 Gene
Grant awards (21)
Atherothrombosis in JAK2V617F clonal hematopoiesis$674,641
R01 · FY2025 · HL · contact PI
The role of eosinophil in thrombosis and atherosclerosis in LNK deficiency$625,296
R01 · FY2025 · HL · contact PI
Mouse and Human Atherosclerotic Tissue$261,024
P01 · FY2025 · HL · contact PI
Atherothrombosis in JAK2V617F clonal hematopoiesis$674,641
R01 · FY2024 · HL · contact PI
The role of eosinophil in thrombosis and atherosclerosis in LNK deficiency$627,174
R01 · FY2024 · HL · contact PI
Mouse and Human Atherosclerotic Tissue$262,563
P01 · FY2024 · HL · contact PI
JAK2V617F, clonal hematopoiesis and atherosclerosis$405,000
R01 · FY2022 · HL · contact PI
Lesion Analysis/Biostatistics Core$322,748
P01 · FY2022 · HL · contact PI
JAK2V617F, clonal hematopoiesis and atherosclerosis$405,000
R01 · FY2021 · HL · contact PI
Lesion Analysis/Biostatistics Core$322,748
P01 · FY2021 · HL · contact PI
JAK2V617F, clonal hematopoiesis and atherosclerosis$405,000
R01 · FY2020 · HL · contact PI
JAK2V617F, clonal hematopoiesis and atherosclerosis$405,000
R01 · FY2020 · HL · contact PI
Lesion Analysis/Biostatistics Core$322,748
P01 · FY2020 · HL · contact PI
JAK2V617F, clonal hematopoiesis and atherosclerosis$405,000
R01 · FY2019 · HL · contact PI
Lesion Analysis/Biostatistics Core$322,748
P01 · FY2019 · HL · contact PI
HDL, platelet progenitors, atherosclerosis and thrombosis$400,000
R01 · FY2018 · HL · contact PI
Lesion Analysis/Biostatistics Core$322,748
P01 · FY2018 · HL · contact PI
HDL, platelet progenitors, atherosclerosis and thrombosis$400,000
R01 · FY2017 · HL · contact PI
HDL, platelet progenitors, atherosclerosis and thrombosis$400,000
R01 · FY2016 · HL · contact PI
HDL, platelet progenitors, atherosclerosis and thrombosis$394,000
R01 · FY2015 · HL · contact PI
HDL, platelet progenitors, atherosclerosis and thrombosis$400,000
R01 · FY2014 · HL · contact PI